EFFECT OF QUERCETIN ON THE INDICATORS OF CARBOHYDRATE AND LIPID METABOLISM IN ELDERLY PEOPLE WITH METABOLIC SYNDROME
Keywords:q uercetin, carbohydrate metabolism, lipid metabolism, elderly age, metabolic syndrome.
Given that oxidative stress plays an important role in the development of metabolic syndrome, a promising direction for the correction of disorders in patients with metabolic syndrome may be the use of antioxidants of plant origin, in particular natural antioxidant quercetin. Aim: To study the effect of quercetin on prediabetic disorders of carbohydrate metabolism and dyslipidemia in elderly patients with metabolic syndrome. Material and methods. Fifty patients with metabolic syndrome at the age of 60-75 years, were examined, which were equally divided into the main and control groups. The patients of the main group received quercetin at a daily dose of 240 mg for 3 months, and the patients of the control group received placebo for the same period. Before and after the course of treatment, indicators of carbohydrate and lipid metabolism were determined. To identify latent disorders of carbohydrate metabolism, all subjects underwent a standard oral glucose tolerance test. Results. The use of quercetin led to a decrease in fasting glucose levels and after 2 h of glucose tolerance test, plasma insulin concentration and HOMA index in patients with prediabetic disorders, and also reduced the frequency of detection of prediabetic disorders of carbohydrate metabolism, in particular, increased fasting glycemia (from 52 to 24%) and impaired carbohydrate tolerance (from 56 to 16%). The course intake of quercetin also led to a statistically significant decrease in total cholesterol, LDL cholesterol and atherogenicity index. In patients of the control group, parameters of carbohydrate and lipid metabolism did not change. Conclusions. The obtained results indicate that in elderly patients with metabolic syndrome а course (within 3 months) use of quercetin reduces prediabetes disorders of carbohydrate metabolism and the manifestation of dyslipidemia.
Shalamaj AS. Kvercetin i Kvertin: bioflavonoidy na strazhe zdorov’ja, Kiev, 2012: 90 p.
Eid НМ, Haddad PS. Curr Med Chem 2017; 24(4): 355-364.
Borikov OJu. Eksperymental’ne obgruntuvannja zastosuvannja kvercetynu dlja korekcii’ metabolichnyh projaviv syndromu insulinorezystentnosti, Harkiv, 2011: 23 p.
Srinivasan P, Vijayakumar S, Kothandaraman S, Palani M. J Pharm Anal 2018; 8: 109-118. doi: http://doi.org/10.1016/j.jpha.2017.10.005.
Gaballah HH, Zakaria SS, Mwafy SE, et al. Biomed Pharmacother 2017; 92: 331-339. doi: http://doi.org/10.1016/j.biopha.2017.05.086.
Zhao LR, Du YJ, Chen L, et al. Int J Mol Med 2014;34(4): 1025-1031. doi: http://doi.org/10.3892/ijmm.2014.1852.
Youl E, Bardy G, Magous R, et al. Br J Pharmacol 2010;161(4): 799-814. doi: http://doi.org/10.1111/j.1476-5381.2010.00910.x.
Hamilton KE, Rekman JF, Gunnink LK, et al. Biochimie 2018; 151:107-114. doi: http://doi.org/10.1016/j.biochi.2018.05.012.
Dhanya R, Arya AD, Nisha P, Jayamurithy P. Front Pharmacol 2017; 8(336): 1-9. doi:http://doi.org/10.3389/fphar.2017.00336.
Choi HN, Jeong SM, Huh H, Kim JI. Food Sci Biotechnol 2015; 24(1): 273-279. doi: http://doi.org/10.1007/s10068-015-0036-9.
Jeong SM, Kang MJ, Choi HN, et al. Nutr Res Pract 2012; 6(3): 201-207. doi: http://doi.org/10.4162/nrp.2012.6.3.201.